Physiomics plc (AIM: PYC) announced on Monday that it has secured a contract with a UK-based biotech company developing antibody-drug conjugate (ADC) therapies for hard-to-treat cancers.
The GBP102,000 project will run from April to August 2025 and focus on developing a pharmacokinetic (PK) and pharmacodynamic (PD) model to optimise dosing for the client's First-in-Human trial.
As a leader in mathematical modelling, data science and biostatistics, Physiomics supports biotech and pharma firms in streamlining drug development.
Leveraging its proprietary Virtual Tumour technology and computational expertise, the company has contributed to over 100 commercial projects, collaborating with clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025